RaySearch Laboratories AB (publ) (RAY_B) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and a warm welcome to the presentation of Research Q3 2025 results. My name is Carolina Strömlid and I'm new head of investor relations at Research. With me today are our founder and CEO Johan Lööf and our CFO Nina Grönberg who will take you through the highlights and financials of the quarter. After the presentation we will open up for questions so feel free to submit them in the chat or ask them live. With that, let's kick off today's presentation. Thank you, Carolina, and welcome again, everyone. Before we go through the Q3 results and highlights, I'd like to give a brief overview of Raysearch and our business. As you know, Raysearch is a pure software company, and we develop software for cancer treatments. four platforms, RayStation, which is our treatment planning system, RayCare, which is the oncology information system, RayTelligence is our analytics tool for exploring population data, and RayCommand is the treatment control system. So if you look at the comprehensive cancer center, we have Usually the radiotherapy treatment in the basement, you see the treatment machines down there. In the comprehensive cancer center you also perform surgery for cancer and you deliver chemotherapy and other systemic therapies. So comprehensive cancer center can deliver all the types of treatments that are available for cancer. Razor has so far, during our first 25 years, been mainly focused on radiotherapy, or I would say only focused on radiotherapy. So we do the treatment planning for radiotherapy and also with Raycare we manage the workflows, et cetera, for delivering radiotherapy. We have recently added a new function in RayStation for deliberation, planning and delivery. So there's a little room in this clinic picture where you see a liver ablation to the fa...